Modifying therapeutic DNA aptamers to keep them in the bloodstream longer

November 29, 2017, Mary Ann Liebert, Inc
Credit: Mary Ann Liebert, Inc., publishers

Designing new therapeutic DNA aptamers with diverse side chains can improve their ability to interact with targets, and a new study describes characteristics of these side chains that may determine how long the aptamers remain in the bloodstream. Improving the pharmacokinetic properties of therapeutic aptamers is an important aspect of optimizing their drug-like properties, as discussed in the study published in Nucleic Acid Therapeutics.

In the article entitled "Pharmacokinetic Properties of DNA Aptamers with Base Modifications," Nebojsa Janjic, SomaLogic (Boulder, CO) and coauthors from SomaLogic and Otsuka Pharmaceutical (Tokushima, Japan), describe what effect the lengths of sequences have on plasma resident time. The researchers also demonstrate the importance of the hydrophobicity of the side chains on their rate of clearance from the bloodstream. The findings can serve as a guide for designing new aptamers with side chains that enhance their diversity.

"This elegant study demonstrates how nucleotide modifications can mitigate against nuclease degradation of aptamers, as vital a concern as is delivery for successful in vivo therapeutic or diagnostic applications," says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI.

Explore further: RNA aptamers targeted to plasminogen activator inhibitor

More information: Shashi Gupta et al, Pharmacokinetic Properties of DNA Aptamers with Base Modifications, Nucleic Acid Therapeutics (2017). DOI: 10.1089/nat.2017.0683

Related Stories

RNA aptamers targeted to plasminogen activator inhibitor

June 19, 2014
Plasminogen activators are proteins involved in the breakdown of blood clots, and an elevated level of plasminogen activator inhibitor-1 (PAI-1) is associated with an increased risk for clotting and cardiovascular disease. ...

A natural sugar delivers DNA aptamer drug inside tumor cells

January 27, 2014
Drugs comprised of single strands of DNA, called aptamers, can bind to targets inside tumor cells causing cell death. But these DNA drugs cannot readily get inside tumor cells on their own. Effective delivery of DNA aptamers ...

Medicine scholars develop innovative targeted delivery system for treating osteosarcoma

November 10, 2017
Chinese Medicine scholars at Hong Kong Baptist University (HKBU) have succeeded in developing a novel targeted delivery system for CRISPR/Cas9 to achieve therapeutic genome editing of VEGFA in osteosarcoma (OS). Their research ...

Recommended for you

Human 'chimeric' cells restore crucial protein in Duchenne muscular dystrophy

March 16, 2018
Cells made by fusing a normal human muscle cell with a muscle cell from a person with Duchenne muscular dystrophy —a rare but fatal form of muscular dystrophy—were able to significantly improve muscle function when implanted ...

Team develops 3-D tissue model of a developing human heart

March 16, 2018
The heart is the first organ to develop in the womb and the first cause of concern for many parents.

Genetic variant discovery to help asthma sufferers

March 16, 2018
Research from the University of Liverpool, published today in Lancet Respiratory Medicine, identifies a genetic variant that could improve the safety and effectiveness of corticosteroids, drugs that are used to treat a range ...

Researchers say use of artificial intelligence in medicine raises ethical questions

March 15, 2018
In a perspective piece, Stanford researchers discuss the ethical implications of using machine-learning tools in making health care decisions for patients.

Study identifies potential drug for treatment of debilitating inherited neurological disease

March 15, 2018
St. Jude Children's Research Hospital scientists have demonstrated in mouse studies that the neurological disease spinal bulbar muscular atrophy (SBMA) can be successfully treated with drugs. The finding paves the way for ...

Clearing clumps of protein in aging neural stem cells boosts their activity

March 15, 2018
Young, resting neural stem cells in the brains of mice store large clumps of proteins in specialized cellular trash compartments known as lysosomes, researchers at the Stanford University School of Medicine have found.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.